{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:59:22Z","timestamp":1786982362725,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP17K10561"],"award-info":[{"award-number":["JP17K10561"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s12282-023-01465-2","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T07:06:24Z","timestamp":1683788784000},"page":"727-738","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Resveratrol exhibits diverse anti-cancer activities through epigenetic regulation of E-cadherin and p21 in triple-negative breast cancer cells"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9733-0548","authenticated-orcid":false,"given":"Takako","family":"Sakamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Tanimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetaka","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunta","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouki","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahoko","family":"Ichihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,11]]},"reference":[{"key":"1465_CR1","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321:288\u2013300.","journal-title":"JAMA"},{"key":"1465_CR2","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1002\/cncr.31307","volume":"124","author":"AA Turk","year":"2018","unstructured":"Turk AA, Wisinski KB. PARP inhibitors in breast cancer: bringing synthetic lethality to the bedside. Cancer. 2018;124:2498\u2013506.","journal-title":"Cancer"},{"key":"1465_CR3","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","volume":"9","author":"AC Garrido-Castro","year":"2019","unstructured":"Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9:176\u201398.","journal-title":"Cancer Discov"},{"key":"1465_CR4","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.3892\/ol.2016.4274","volume":"11","author":"J Liu","year":"2016","unstructured":"Liu J, Sun X, Qin S, Wang H, Du N, Li Y, et al. CDH1 promoter methylation correlates with decreased gene expression and poor prognosis in patients with breast cancer. Oncol Lett. 2016;11:2635\u201343.","journal-title":"Oncol Lett"},{"key":"1465_CR5","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1093\/ajcp\/aqw183","volume":"146","author":"T Shen","year":"2016","unstructured":"Shen T, Zhang K, Siegal GP, Wei S. Prognostic value of E-cadherin and \u03b2-catenin in triple-negative breast cancer. Am J Clin Pathol. 2016;146:603\u201310.","journal-title":"Am J Clin Pathol"},{"key":"1465_CR6","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.yexcr.2017.04.006","volume":"358","author":"A Kourtidis","year":"2017","unstructured":"Kourtidis A, Lu R, Pence LJ, Anastasiadis PZ. A central role for cadherin signaling in cancer. Exp Cell Res. 2017;358:78\u201385.","journal-title":"Exp Cell Res"},{"key":"1465_CR7","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1038\/onc.2010.215","volume":"29","author":"A Singh","year":"2010","unstructured":"Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29:4741\u201351.","journal-title":"Oncogene"},{"key":"1465_CR8","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1093\/annonc\/mdn402","volume":"19","author":"G Somlo","year":"2008","unstructured":"Somlo G, Chu P, Frankel P, Ye W, Groshen S, Doroshow JH, et al. Molecular profiling including epidermal growth factor receptor and p21 expression in high-risk breast cancer patients as indicators of outcome. Ann Oncol. 2008;19:1853\u20139.","journal-title":"Ann Oncol"},{"key":"1465_CR9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s12282-018-0913-1","volume":"26","author":"SF Zohny","year":"2019","unstructured":"Zohny SF, Al-Malki AL, Zamzami MA, Choudhry H. p21Waf1\/Cip1: its paradoxical effect in the regulation of breast cancer. Breast Cancer. 2019;26:131\u20137.","journal-title":"Breast Cancer"},{"key":"1465_CR10","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.molmed.2017.02.001","volume":"23","author":"AG Georgakilas","year":"2017","unstructured":"Georgakilas AG, Martin OA, Bonner WM. p21: a two-faced genome guardian. Trends Mol Med. 2017;23:310\u20139.","journal-title":"Trends Mol Med"},{"key":"1465_CR11","doi-asserted-by":"publisher","first-page":"731","DOI":"10.3390\/nu10060731","volume":"10","author":"AK Singh","year":"2018","unstructured":"Singh AK, Bishayee A, Pandey AK. Targeting histone deacetylases with natural and synthetic agents: an emerging anticancer strategy. Nutrients. 2018;10:731.","journal-title":"Nutrients"},{"key":"1465_CR12","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.drudis.2019.02.003","volume":"24","author":"MK Ediriweera","year":"2019","unstructured":"Ediriweera MK, Tennekoon KH. Samarakoon SR emerging role of histone deacetylase inhibitors as anti-breast-cancer agents. Drug Discov Today. 2019;24:685\u2013702.","journal-title":"Drug Discov Today"},{"key":"1465_CR13","doi-asserted-by":"publisher","first-page":"R79","DOI":"10.1186\/bcr3192","volume":"14","author":"CR Tate","year":"2012","unstructured":"Tate CR, Rhodes LV, Segar HC, Driver JL, Pounder FN, Burow ME, et al. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Cancer Res. 2012;14:R79.","journal-title":"Breast Cancer Res"},{"key":"1465_CR14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10549-013-2784-7","volume":"143","author":"P Shah","year":"2014","unstructured":"Shah P, Gau Y, Sabnis G. Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin. Breast Cancer Res Treat. 2014;143:99\u2013111.","journal-title":"Breast Cancer Res Treat"},{"key":"1465_CR15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3389\/fgene.2019.00079","volume":"10","author":"\u00c1 Carlos-Reyes","year":"2019","unstructured":"Carlos-Reyes \u00c1, L\u00f3pez-Gonz\u00e1lez JS, Meneses-Flores M, Gallardo-Rinc\u00f3n D, Ru\u00edz-Garcia E, Marchat LA, et al. Dietary compounds as epigenetic modulating agents in cancer. Front Genet. 2019;10:79.","journal-title":"Front Genet"},{"key":"1465_CR16","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1002\/biof.1544","volume":"45","author":"B Chatterjee","year":"2019","unstructured":"Chatterjee B, Ghosh K, Kanade SR. Resveratrol modulates epigenetic regulators of promoter histone methylation and acetylation that restores BRCA1, p53, p21CIP1 in human breast cancer cell lines. BioFactors. 2019;45:818\u201329.","journal-title":"BioFactors"},{"key":"1465_CR17","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.semcancer.2015.11.001","volume":"40\u201341","author":"D Sinha","year":"2016","unstructured":"Sinha D, Sarkar N, Biswas J, Bishayee A. Resveratrol for breast cancer prevention and therapy: preclinical evidence and molecular mechanisms. Semin Cancer Biol. 2016;40\u201341:209\u201332.","journal-title":"Semin Cancer Biol"},{"key":"1465_CR18","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.jnutbio.2009.06.010","volume":"21","author":"T Sakamoto","year":"2010","unstructured":"Sakamoto T, Horiguchi H, Oguma E, Kayama F. Effects of diverse dietary phytoestrogens on cell growth, cell cycle and apoptosis in estrogen-receptor-positive breast cancer cells. J Nutr Biochem. 2010;21:856\u201364.","journal-title":"J Nutr Biochem"},{"key":"1465_CR19","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.yexcr.2018.06.031","volume":"370","author":"S Ji","year":"2018","unstructured":"Ji S, Zheng Z, Liu S, Ren G, Gao J, Zhang Y, et al. Resveratrol promotes oxidative stress to drive DLC1 mediated cellular senescence in cancer cells. Exp Cell Res. 2018;370:292\u2013302.","journal-title":"Exp Cell Res"},{"key":"1465_CR20","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.taap.2013.05.011","volume":"272","author":"H Li","year":"2013","unstructured":"Li H, Huang J, Yang B, Xiang T, Yin X, Peng W, et al. Mangiferin exerts antitumor activity in breast cancer cells by regulating matrix metalloproteinases, epithelial to mesenchymal transition, and \u03b2-catenin signaling pathway. Toxicol Appl Pharmacol. 2013;272:180\u201390.","journal-title":"Toxicol Appl Pharmacol"},{"key":"1465_CR21","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s10549-014-2979-6","volume":"145","author":"LV Rhodes","year":"2014","unstructured":"Rhodes LV, Tate CR, Segar HC, Burks HE, Phamduy TB, Hoang V, et al. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators. Breast Cancer Res Treat. 2014;145:593\u2013604.","journal-title":"Breast Cancer Res Treat"},{"key":"1465_CR22","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nm.4010","volume":"22","author":"J Chang","year":"2016","unstructured":"Chang J, Wang Y, Shao L, Laberge RM, Demaria M, Campisi J, et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat Med. 2016;22:78\u201383.","journal-title":"Nat Med"},{"key":"1465_CR23","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.3109\/10428194.2015.1030638","volume":"56","author":"TJ Kipps","year":"2015","unstructured":"Kipps TJ, Eradat H, Grosicki S, Catalano J, Cosolo W, Dyagil IS, et al. A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2015;56:2826\u201333.","journal-title":"Leuk Lymphoma"},{"key":"1465_CR24","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1038\/aps.2017.78","volume":"38","author":"QH Lin","year":"2017","unstructured":"Lin QH, Que FC, Gu CP, Zhong DS, Zhou D, Kong Y, et al. ABT-263 induces G1\/G0-phase arrest, apoptosis and autophagy in human esophageal cancer cells in vitro. Acta Pharmacol Sin. 2017;38:1632\u201341.","journal-title":"Acta Pharmacol Sin"},{"key":"1465_CR25","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1111\/bph.12659","volume":"171","author":"J Li","year":"2014","unstructured":"Li J, Chen Y, Wan J, Liu X, Yu C, Li W. ABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21(CIP1\/WAF1) in human cancer cells. Br J Pharmacol. 2014;171:3182\u201395.","journal-title":"Br J Pharmacol"},{"key":"1465_CR26","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0303-7207(02)00086-2","volume":"192","author":"T Sakamoto","year":"2002","unstructured":"Sakamoto T, Eguchi H, Omoto Y, Ayabe T, Mori H, Hayashi S. Estrogen receptor-mediated effects of tamoxifen on human endometrial cancer cells. Mol Cell Endocrinol. 2002;192:93\u2013104.","journal-title":"Mol Cell Endocrinol"},{"key":"1465_CR27","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jsbmb.2017.04.001","volume":"171","author":"K Tsuboi","year":"2017","unstructured":"Tsuboi K, Nagatomo T, Gohno T, Higuchi T, Sasaki S, Fujiki N, et al. Single CpG site methylation controls estrogen receptor gene transcription and correlates with hormone therapy resistance. J Steroid Biochem Mol Biol. 2017;171:209\u201317.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"1465_CR28","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/mnfr.200700185","volume":"52","author":"AK Marel","year":"2008","unstructured":"Marel AK, Lizard G, Izard JC, Latruffe N, Delmas D. Inhibitory effects of trans-resveratrol analogs molecules on the proliferation and the cell cycle progression of human colon tumoral cells. Mol Nutr Food Res. 2008;52:538\u201348.","journal-title":"Mol Nutr Food Res"},{"key":"1465_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.32607\/20758251-2015-7-2-17-28","volume":"7","author":"NV Krakhmal","year":"2015","unstructured":"Krakhmal NV, Zavyalova MV, Denisov EV, Vtorushin SV, Perelmuter VM. Cancer invasion: patterns and mechanisms. Acta Naturae. 2015;7:17\u201328.","journal-title":"Acta Naturae"},{"key":"1465_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.636213","volume":"12","author":"X Chen","year":"2021","unstructured":"Chen X, Wang Y, Tian J, Shao Y, Zhu B, Wang J, et al. Quantitative chemical proteomics reveals resveratrol inhibition of A549 cell migration through binding multiple targets to regulate cytoskeletal remodeling and suppress EMT. Front Pharmacol. 2021;12: 636213.","journal-title":"Front Pharmacol"},{"key":"1465_CR31","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3390\/cancers5020334","volume":"5","author":"J Roche","year":"2013","unstructured":"Roche J, Nasarre P, Gemmill R, Baldys A, Pontis J, Korch C, et al. Global decrease of histone H3K27 acetylation in ZEB1-induced epithelial to mesenchymal transition in lung cancer cells. Cancers (Basel). 2013;5:334\u201356.","journal-title":"Cancers (Basel)"},{"key":"1465_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157866","volume":"11","author":"R Medina-Aguilar","year":"2016","unstructured":"Medina-Aguilar R, P\u00e9rez-Plasencia C, Marchat LA, Gariglio P, Garc\u00eda Mena J, Rodr\u00edguez Cuevas S, et al. Methylation landscape of human breast cancer cells in response to dietary compound resveratrol. PLoS\u00a0One. 2016;11: e0157866.","journal-title":"PLoS\u00a0One"},{"key":"1465_CR33","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1111\/cas.14116","volume":"110","author":"T Inao","year":"2019","unstructured":"Inao T, Kotani H, Iida Y, Kartika ID, Okimoto T, Tanino R, et al. Different sensitivities of senescent breast cancer cells to immune cell-mediated cytotoxicity. Cancer Sci. 2019;110:2690\u20139.","journal-title":"Cancer Sci"},{"key":"1465_CR34","doi-asserted-by":"publisher","first-page":"R148","DOI":"10.1186\/bcr3358","volume":"14","author":"C Thomas","year":"2012","unstructured":"Thomas C, Rajapaksa G, Nikolos F, Hao R, Katchy A, McCollum CW, et al. ER\u03b21 represses basal-like breast cancer epithelial to mesenchymal transition by destabilizing EGFR. Breast Cancer Res. 2012;14:R148.","journal-title":"Breast Cancer Res"},{"key":"1465_CR35","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1210\/endo.142.9.8395","volume":"142","author":"G Lazennec","year":"2001","unstructured":"Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F. ER\u03b2 inhibits proliferation and invasion of breast cancer cells. Endocrinology. 2001;142:4120\u201330.","journal-title":"Endocrinology"},{"key":"1465_CR36","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1210\/endo.141.10.7721","volume":"141","author":"JL Bowers","year":"2000","unstructured":"Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM. Resveratrol acts as a mixed agonist\/antagonist for estrogen receptors \u03b1 and \u03b2. Endocrinology. 2000;141:3657\u201367.","journal-title":"Endocrinology"},{"key":"1465_CR37","doi-asserted-by":"publisher","first-page":"5255","DOI":"10.3390\/ijms22105255","volume":"22","author":"A Chimento","year":"2021","unstructured":"Chimento A, Santarsiero A, Iacopetta D, Ceramella J, De Luca A, Infantino V, et al. A phenylacetamide resveratrol derivative exerts inhibitory effects on breast cancer cell growth. Int J Mol Sci. 2021;22:5255.","journal-title":"Int J Mol Sci"},{"key":"1465_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120975","volume":"607","author":"K Ren","year":"2021","unstructured":"Ren K, Qiu Y, Yu Q, He J, Mei L, Liu Y, et al. Macrophage-mediated multi-mode drug release system for photothermal combined with anti-inflammatory therapy against postoperative recurrence of triple negative breast cancer. Int J Pharm. 2021;607: 120975.","journal-title":"Int J Pharm"},{"key":"1465_CR39","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/j.1749-6632.2010.05853.x","volume":"1215","author":"KR Patel","year":"2011","unstructured":"Patel KR, Scott E, Brown VA, Gescher AJ, Steward WP, Brown K. Clinical trials of resveratrol. Ann N Y Acad Sci. 2011;1215:161\u20139.","journal-title":"Ann N Y Acad Sci"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-023-01465-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-023-01465-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-023-01465-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T10:06:03Z","timestamp":1691229963000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-023-01465-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,11]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1465"],"URL":"https:\/\/doi.org\/10.1007\/s12282-023-01465-2","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,11]]},"assertion":[{"value":"20 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}